David Rodman, M.D., serves as the Chief Medical Officer at MINERALYS THERAPEUTICS INC, where he plays a pivotal role in advancing the company's mission to develop innovative therapies for patients with serious diseases. Dr. Rodman brings a wealth of experience to his position, having spent over two decades in the pharmaceutical and biotechnology industries. Prior to joining MINERALYS, he held several leadership roles, including Chief Medical Officer at multiple clinical-stage biopharmaceutical companies, where he was instrumental in guiding drug development programs from early-stage research through to successful regulatory approval and commercialization. Dr. Rodman's professional background is marked by his extensive expertise in clinical development, particularly in the fields of cardiovascular and metabolic diseases. He has been involved in the development of numerous drug candidates, contributing to the design and execution of clinical trials that have led to significant advancements in patient care. His strategic vision and deep understanding of the regulatory landscape have been key factors in his ability to navigate the complex process of bringing new therapies to market. Dr. Rodman's achievements include leading teams that have secured multiple FDA approvals, underscoring his commitment to improving health outcomes for patients worldwide. In his current role at MINERALYS THERAPEUTICS INC, Dr. Rodman is responsible for overseeing the clinical development strategy and execution of the company's pipeline. His leadership is crucial in ensuring that the company's innovative approaches to treating hypertension and other related conditions are translated into effective and safe treatments. Dr. Rodman's dedication to scientific excellence and patient-centric care continues to drive MINERALYS forward, positioning the company as a leader in the development of novel therapies for underserved medical needs.